Clinical trials involving novel targeted agents have demonstrated little success as palliative treatment for GC, with the exceptions of trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive tumors [2], and ramucirumab as a second-line treatment [3, 4]. This evidence concerns the gene ERBB2 and gastric cancer.